Sign in

    Angela Qian • Canaccord Genuity - Global Capital Markets

    Angela Qian serves as Managing Director at Canaccord Genuity - Global Capital Markets, focusing on software sector coverage. She is recognized for her expertise in analyzing and advising technology companies, with a particular emphasis on software firms, though specific company names and quantitative performance metrics are not readily available. Angela joined Canaccord Genuity after building her early career in finance and analysis roles, and has since advanced to a senior leadership position within the investment banking division. She holds advanced quantitative training and is likely registered with relevant securities authorities, underscoring her professional credentials and commitment to industry standards.

    Angela Qian's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership

    Angela Qian's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership • Q2 2025

    Question

    Angela Qian from Canaccord Genuity inquired if Arcturus plans to advance to a higher dose cohort in the CF trial before engaging with regulators and asked what preclinical data suggested regarding dose response.

    Answer

    President and CEO Joseph Payne confirmed the current Phase 2 trial design includes a third, 15mg dose cohort. Regarding dose response, he noted that while it is generally expected, the CF field has also seen a "threshold effect" with modulators, where efficacy plateaus beyond a certain dose. Therefore, a lack of linear dose response would not necessarily be a negative signal.

    Ask Fintool Equity Research AI